Prot# PTG-100-02: A Phase 2B Randomized, Double-Blind, Placebo-Controlled, Parallel Adaptive 2-Stage, Multi-Centre Study to Evaluate the Safety and Efficacy of Oral PTG-100 Induction in Subjects with Moderate to Severe Active Ulcerative Colitis

Project: Research project

Project Details

StatusFinished
Effective start/end date7/12/17 → 7/12/20

Funding

  • Covance Inc. (Prot# PTG-100-02)
  • Protagonist Therapeutics, Inc. (Prot# PTG-100-02)